Biocardis

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biocardis

Property Description
Active ingredient Telmisartan
Form Oral tablets
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of high blood pressure (Antihypertensive)
Origin Synthetic drug (Benzimidazole derivative)

Biocardis: Classification and Chemical Foundation

Biocardis is a prescription-only medicine for systemic action that contains the single active ingredient Telmisartan. This drug is classified pharmacologically as an Angiotensin II Receptor Blocker (ARB), placing it within the group commonly referred to as Sartans. Telmisartan is a synthetic drug that originates as a non-peptide benzimidazole derivative. This classification relates to the drug’s ability to selectively interfere with the body’s vascular regulatory pathways.

The core purpose of classifying Biocardis as an ARB is to define its functional role in the body's natural regulation of blood pressure. This targeted mechanism is utilized in patient populations where specific vascular modulation is necessary. Biocardis is a therapeutic entity utilized for the long-term management of elevated blood pressure, otherwise known as systemic hypertension.


Mechanism, Purpose, and Pharmaceutical Form

The fundamental purpose of Telmisartan is to produce a sustained antihypertensive effect by promoting the relaxation and widening of arteries. It achieves this by acting as a specific blocker that prevents the natural chemical, Angiotensin II, from binding to its primary receptor site on blood vessels. The resulting reduction in the overall pressure against which the heart must pump blood is the primary effect of Biocardis.

Biocardis is supplied exclusively as oral tablets and is designed for systemic action upon ingestion. The specific tablet formulation for Biocardis ensures reliable absorption, which is intended for consistent management in an adult patient population. Telmisartan tablets are used for the treatment of essential hypertension.

Regulatory References

  1. Summary of Telmisartan EPAR

What side effects are possible with Biocardis?

Possible side effects and safety information

The safety profile for Biocardis (Telmisartan) is formally documented in government regulatory labeling, categorizing adverse reactions by the physiological system affected and the expected frequency of occurrence.

Adverse Reaction Classification

Adverse effects are listed by frequency, with Common effects (geq1/100) including upper respiratory tract infection, sinusitis, back pain, and diarrhea. Uncommon effects (geq1/1,000) include anemia, hyperkalaemia, syncope (fainting), hypotension, cough, renal impairment (including acute renal failure), and chest pain. Rare effects (geq1/10,000) include sepsis (including fatal outcome), anaphylactic reaction, and angioedema. Certain events, such as Interstitial lung disease, are reported in the post-marketing phase.

Adverse reactions are grouped into System Organ Classes (SOCs) such as Vascular Disorders, Metabolism and Nutrition Disorders (e.g., hyperkalaemia), Renal and Urinary Disorders, and Musculoskeletal and Connective Tissue Disorders.

Documented Serious Adverse Reactions and Restrictions

Official labeling emphasizes serious safety considerations. Fetal Toxicity is a major restriction; use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus. The medication is also Contraindicated in patients with known hypersensitivity (e.g., prior angioedema) and in those with severe hepatic impairment, cholestasis, or biliary obstructive disorders due to its elimination pathway. Symptomatic Hypotension may occur, particularly after treatment initiation in volume- or salt-depleted patients. The label notes an increased risk of hypoglycaemia specifically in diabetic patients.

Regular monitoring of renal function and serum potassium levels is recommended for susceptible patients. The use of this drug is generally avoided in combination with aliskiren in diabetic patients.

This structured regulatory information establishes the official boundaries for the safe use of this medicine, defining the range of possible outcomes and critical constraints related to specific patient populations.

Overdose and Emergency Response

The regulatory documentation for Biocardis (Telmisartan) specifies that an overdose is most likely to manifest as a severe exaggeration of its blood-pressure-lowering effect, known as profound hypotension. Other formally documented clinical findings may include disturbances in heart rhythm, specifically tachycardia (fast heart rate), or, conversely, bradycardia (slow heart rate). Symptoms such as dizziness and fainting are also associated with severe low blood pressure in overdose scenarios.

When to Seek Immediate Help

Government health authorities mandate urgent action if the overdose leads to life-threatening manifestations. Individuals must seek immediate medical attention and contact emergency services if the affected person exhibits critical signs, including a seizure, trouble breathing, or loss of consciousness (e.g., cannot be awakened). The Poison Control Helpline should also be contacted for immediate guidance.

Management and Monitoring

The required management for overdose is symptomatic and supportive treatment to address the clinical presentation, particularly if severe hypotension occurs. Official labeling notes that no specific antidote is known, and Telmisartan is not effectively removed from the body by hemodialysis. A specific caution exists for infants with in utero exposure to the drug class, who require close medical observation due to the risk of severe complications like hypotension and hyperkalemia.

Therapeutic Uses of Biocardis

What Biocardis Treats: Main Uses and Benefits

Biocardis is commonly used to manage chronic conditions involving systemic imbalance, targeting specific therapeutic domains. The primary clinical situations where it is applied involve the long-term management of essential hypertension and support for managing major cardiovascular risk.

The medication is generally used to support sustained blood pressure management and assists with maintaining stability over daily periods, which is relevant for managing symptoms linked to organ-specific functional stress. Indications relevant to this therapy include essential hypertension, support for managing the risk of stroke and heart attack, and support for organ function, particularly in patients with conditions marked by increased physiological stress, like type 2 diabetes. The treatment contributes to support for organ function during situations involving cumulative stress related to hypertension.


Quick Fact: Support for Blood Pressure

The therapy is commonly used to support sustained blood pressure management, which helps ease the overall symptom load and may assist with maintaining functional stability for adults with chronic essential hypertension.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Biocardis

Official regulatory documentation for Biocardis (Telmisartan) defines strict population-based eligibility rules and absolute contraindications.


Contraindicated Populations

Population/Condition Eligibility Status
Pregnancy (2nd & 3rd Trimester) Contraindicated (Must be discontinued immediately upon detection)
Severe Hepatic Impairment / Biliary Disorders Contraindicated
Known Hypersensitivity Contraindicated (To telmisartan or any tablet component)
Diabetes or Moderate-to-Severe Renal Impairment (GFR < 60 mL/min/1.73 m^2) plus Aliskiren Contraindicated

Age-Related and Conditional Use

  • Adults (ge18 years): Use is allowed for the management of hypertension and, for those ge55 years, for cardiovascular risk reduction.
  • Pediatric Population (< 18 years): Use is not recommended as safety and efficacy have not been established.
  • Pregnancy (1st Trimester) / Lactation: Use is not recommended.
  • Mild to Moderate Hepatic Impairment: Use is allowed but restricted; dose adjustment is specified by regulators.
  • Volume/Salt Depletion: Use is conditional; this state must be corrected prior to beginning therapy.

Connection to the overall eligibility profile

Regulatory documents establish absolute non-eligibility for specific organ disorders and life stages, such as severe hepatic impairment and the second half of pregnancy. Eligibility is also restricted based on concomitant medication (Aliskiren) and pre-existing conditions (diabetes). Use is confirmed as allowed only for the established adult population with hypertension or high cardiovascular risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Biocardis (Telmisartan) interactions are categorized by regulatory authorities based on their impact on plasma concentration, potential for additive effects on blood pressure or electrolytes, and specific population-based restrictions.

Contraindicated and Restricted Combinations

Co-administration with Aliskiren is formally contraindicated in patients with diabetes mellitus or in patients who have moderate-to-severe renal impairment (GFR <60 mL/min/1.73 m^2) due to the risks of dual blockade of the Renin-Angiotensin System (RAS).

Combination with ACE Inhibitors is not recommended due to increased risks of hypotension, hyperkalemia, and changes in renal function.

Pharmacokinetic and Pharmacodynamic Interactions

Telmisartan acts as an inhibitor of the efflux transporter P-glycoprotein (P-gp). This pharmacokinetic interaction leads to a documented increase in the plasma concentration ( C max and trough) of co-administered P-gp substrates, such as Digoxin. Regulatory guidance requires plasma level monitoring when initiating or adjusting this combination.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a reduction in the antihypertensive effect of Telmisartan and increase the risk of renal function deterioration, particularly in the elderly or volume-depleted patients.

Interactions with Supplements and Substances

Concurrent use of Potassium supplements or Potassium-containing salt substitutes increases the risk of hyperkalemia (elevated serum potassium levels). Additionally, the use of Lithium is associated with reduced clearance, elevating the risk of toxicity. The regulatory information notes that Alcohol (Ethanol) may result in an additive blood pressure-lowering effect.

Mechanism of Action

Biocardis functions as a direct, selective antagonist at the beta1-adrenergic receptor subtype. This action is preferentially expressed in cardiomyocyte membranes, where the beta1 receptor population is dominant.

The molecular interaction involves Biocardis competing with endogenous catecholamines (e.g., norepinephrine) for the orthosteric binding pocket on the transmembrane beta1 receptor. By occupying this site, the compound prevents receptor conformational change and subsequent G-protein coupling (specifically Gs protein activation).

The prevention of Gs protein activation directly blocks the stimulation of the enzyme adenylyl cyclase. A reduction in adenylyl cyclase activity results in a decreased intracellular concentration of the second messenger, cyclic adenosine monophosphate (cAMP).

The diminished cAMP concentration leads to reduced activation of Protein Kinase A (PKA). PKA is responsible for phosphorylating key intracellular targets, including L-type calcium channels, phospholamban, and troponin I.

The resulting downstream molecular consequences are: reduced calcium flux across the sarcolemma and sarcoplasmic reticulum, and decreased sensitivity of contractile proteins to calcium. System-level physiological modulation manifests as a negative chronotropic effect (reduction in heart rate via SA node action potential firing rate) and a negative inotropic effect (reduction in myocardial contractility). This integrated action results in a decrease in cardiac output.

Dosage and Administration Information

How Biocardis is Used: Dosing and Administration

This section details the instructions for the use of Biocardis (Telmisartan) in adults, focusing on administration and standard dosing.

Administration and Timing

Biocardis is used via a single, non-invasive route of administration and is supplied exclusively as oral tablets. The tablets must be taken with liquid and can be administered with or without food. It is recommended to take the dose once daily at approximately the same time each day to maintain consistent management.

The tablets are sensitive to moisture and must be removed from the sealed blister pack immediately before ingestion.

Standard Adult Dosing Regimens

Dosing is individualized based on clinical requirements. The following regimens are based on standard recommendations for adults.

Indication Starting Dose Maximum Recommended Dose
Essential Hypertension 40 mg once daily 80 mg once daily
Cardiovascular Risk Reduction 80 mg once daily 80 mg once daily

The majority of the antihypertensive effect is typically achieved within two weeks, with the maximal effect observed after four to eight weeks. Dosage adjustments, if required, are generally made only after a minimum of two weeks of treatment.

Population-Specific Use

No initial dosage adjustment is necessary for older adults or patients with renal impairment. However, for patients with mild to moderate hepatic impairment, the total daily dose is recommended not to exceed 40 mg. If a dose is missed, the next dose should be taken at the usual time; a double dose should not be taken to make up for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase I and II Trials: Initial Safety and Dosing

Early-stage research aimed to characterize the preliminary pharmacokinetic and tolerability profile of the agent.

  • Phase I trials concentrated on dose-ranging evaluation and assessment of the agent's absorption, distribution, metabolism, and excretion (ADME).
  • Phase II studies began investigating the agent’s activity and measures of effect in small, selected cohorts.
  • The results of these initial studies were used to inform the design of larger-scale trials.
  • Research has explored the potential for a combined approach involving this agent and established treatments.

Phase III Trials: Efficacy and Long-Term Outcomes

Research has focused on this agent in randomized controlled trials (RCTs) to evaluate its performance against placebo or active comparators.

  • Primary Outcome Analysis: Research has investigated the agent's effect on motor function scores, a key measure in this disease state.
    • One large, multi-center study evaluated the agent's effect on pain ratings associated with the condition. The study reported findings related to symptom measurement endpoints over a 12-week period.
    • Other studies examined various quality-of-life indicators. Findings were mixed on self-reported patient assessments.
  • Safety and Tolerability: Its tolerability profile was evaluated in adult populations across various dose levels.
    • The most frequently reported side effects in the main trials were mild-to-moderate and included fatigue and gastrointestinal discomfort.
    • Studies have indicated a need for specific review in participants with severe kidney impairment.
    • Research provided data on the agent's interaction profile based on in vitro studies.

Mechanism of Action

The mechanism of action was evaluated in preclinical research focusing on specific neurotransmitter receptors. Preclinical animal models provided data supporting the proposed mechanism.

  • Combination Therapies: Studies are currently evaluating whether combining the agent with X is associated with a change in treatment outcome. Initial phase II data provided exploratory measurement results in a subpopulation of participants, but evidence remains limited, and further investigation is ongoing.

Frequently Asked Questions (FAQ)

Common questions about Biocardis (FAQ)

Q: How quickly does Biocardis start working after the first dose?

According to the official product information, the onset of the medicine's blood pressure-lowering activity is described as beginning within approximately three hours after a single dose is administered. However, the full effect that helps manage your condition may take longer to develop.

Q: What is the difference between Biocardis and [Generic Name]?

Biocardis is a brand name for the medicine, and the active ingredient is generically known as telmisartan. This classification means that telmisartan is the core chemical substance responsible for the drug’s effects.

Q: Is Biocardis safe to use with over-the-counter pain relievers like ibuprofen?

Official documents state that non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may reduce the expected blood pressure-lowering effect of Biocardis. Regulatory warnings mention that this combination is associated with an increased risk of changes in kidney function, particularly in susceptible individuals.

Q: Can I take vitamins or supplements while on Biocardis?

Regulatory documents specifically note that certain supplements, such as potassium supplements or potassium-containing salt substitutes, increase the risk of elevated serum potassium levels (hyperkalemia). Monitoring and caution are noted considerations regarding this documented interaction.

Q: Why is it important to tell my doctor about all the medicines I take while using Biocardis?

Official regulatory information lists documented interactions between Biocardis and several other types of medicine, including lithium and certain heart medications. Disclosing all medicines is important for allowing healthcare providers to monitor for and manage the potential for these documented risks.

Q: Is Biocardis a long-term treatment or just for a short time?

This medicine is typically indicated for the long-term management of chronic conditions, such as elevated blood pressure. Clinical trials have examined the sustained effect of Biocardis over periods of at least one year.

Q: Are there common household foods or drinks that interact with Biocardis?

Regulatory documents specify that Biocardis may be taken with or without food. There are no general restrictions related to typical household foods or non-alcoholic drinks, although alcohol and salt substitutes are specifically noted in the interactions section.

Q: Does Biocardis make you feel tired or drowsy?

The official product information lists two related effects: fatigue was one of the most frequently reported side effects in clinical trials. Somnolence (drowsiness) has also been reported, but in rare instances.

Q: Is it common to have headaches when starting Biocardis?

Official regulatory information lists headache as a reported adverse reaction. Like other possible side effects, the frequency of headaches can vary among individuals.

Q: Can Biocardis affect my ability to drive or operate machinery?

Regulatory information notes that the medicine may cause effects like dizziness or changes in vision. Official patient information states that caution should be exercised when performing tasks that require concentration, such as driving or operating machinery.

Q: Is Biocardis known to cause weight gain or weight loss?

Weight changes are not typically listed as common side effects. However, rapid or unusual weight gain along with swelling in the feet or ankles is noted in safety information as a sign that should be monitored.

Q: What does the research say about the long-term use of Biocardis?

Regulatory information confirms that the effect of the medicine was examined in long-term studies for periods of at least one year. These studies indicated that the blood pressure-lowering effect appeared to be maintained over time.

Q: Are there any known issues with taking Biocardis and birth control pills?

Official warnings emphasize the critical need to use effective birth control while taking Biocardis to avoid pregnancy, which is a major safety restriction. No specific contraindication with the function of oral contraceptives is commonly listed.

Q: Can men taking Biocardis experience any side effects specific to them?

The regulatory information reports Erectile dysfunction under the system organ class of Reproductive System and Breast Disorders. This is listed as a potential adverse reaction.

Q: Are there special considerations for women taking Biocardis?

The most critical consideration is pregnancy, as use during the second and third trimesters can cause injury to the developing fetus. Use during the first trimester or while breastfeeding is also not recommended by regulatory bodies.

Q: How is Biocardis different from a beta-blocker?

Biocardis is classified as an Angiotensin II Receptor Blocker (ARB), which works by blocking the effects of the hormone Angiotensin II on specific receptors. A beta-blocker is a different class of drug that acts on a different set of receptors.

Q: Is Biocardis an addictive medication?

Regulatory information indicates that Biocardis is not classified as a controlled substance and has no Drug Enforcement Administration (DEA) schedule designation, meaning it does not have the legal potential for abuse or dependence.

Q: Is it true that Biocardis is a relatively new medicine?

Official authorization records show that the active ingredient, telmisartan, received its initial marketing authorization in the European Union in December 1998. This date indicates its initial availability as a pharmaceutical product.

Q: Does Biocardis change how my body uses other drugs?

Regulatory information notes that the medicine acts as an inhibitor of the efflux transporter P-glycoprotein (P-gp). This means it can affect how the body handles other medicines that rely on this specific transporter for clearance, potentially leading to increased concentrations of those drugs in the bloodstream.

Q: Is there a maximum time someone can take Biocardis?

Biocardis is indicated for the long-term management of chronic conditions. Its effect was maintained during clinical trials lasting at least one year, and no absolute maximum treatment duration is specified in official documents.

Q: Why is Biocardis sometimes given with another drug?

Official guidelines state that Biocardis may be used alone or in combination with other blood pressure-lowering agents. This is often done when control of high blood pressure requires the complementary effects of more than one medicine.

Q: Does Biocardis have different effects on children compared to adults?

The medicine is generally not recommended for use in children under 18 years of age because safety and efficacy have not been formally established in that population according to regulatory bodies.

Q: What are the signs that Biocardis is working for me?

Since the medicine is intended to lower blood pressure, the primary objective sign that it is working is a reduction in blood pressure readings. Because high blood pressure often has no symptoms, patients often do not feel a subjective change when their pressure is lowered.

Q: If I feel better, can I stop taking Biocardis?

Discontinuing the medicine, even if symptoms improve, may result in an increase in blood pressure. Biocardis is intended for continuous management to help maintain blood pressure control.

Q: What if Biocardis does not seem to be working for me?

Regulatory documents indicate that the majority of the blood pressure-lowering effect is typically seen within two weeks, with the maximal effect expected after four to eight weeks. The medicine requires this time to reach its full potential.

Q: Does Biocardis cause dry mouth or changes in taste?

Official documents list dry mouth and dysgeusia (a change in the sense of taste) as rare adverse reactions.

Q: Is it possible to be allergic to Biocardis?

Yes, official documentation lists hypersensitivity and anaphylactic reaction under adverse reactions. A known hypersensitivity to telmisartan or any tablet component is a formal contraindication to its use.

Q: Do certain activities become risky while on Biocardis?

Regulatory information notes that the effects of the medicine, such as dizziness or light-headedness, may be increased by factors like hot weather, exercise, fever, or alcohol. Caution is advised during activities where these effects could be hazardous.

Q: What is the standard time it takes for a full benefit from Biocardis to be noticed?

Regulatory documents indicate that the maximal blood pressure reduction from the treatment is generally attained after four to eight weeks of use. This timeframe is necessary for the medicine to establish its consistent effect in the body.

Q: Does Biocardis affect sleep patterns?

Official documentation lists insomnia (difficulty sleeping) under the category of psychiatric disorders as an uncommon adverse reaction.

Q: Can Biocardis affect my mood or mental clarity?

Adverse reactions listed in official documents include changes to mood such as depression (uncommon) and anxiety (rare), which are categorized under psychiatric disorders.

Q: Is it possible that Biocardis is causing my stomach upset?

The research evidence for Biocardis indicated that gastrointestinal discomfort was one of the most frequently reported mild-to-moderate side effects in clinical trials. Other uncommon GI side effects listed include diarrhea and abdominal pain.

Q: Is there a risk of withdrawal symptoms if Biocardis is stopped suddenly?

Official documents do not typically use the term 'withdrawal symptoms' but note that blood pressure generally returns to pre-treatment levels over a period of several days to one week if the medicine is discontinued.

Q: What if I take Biocardis and then drink alcohol?

The regulatory information notes that consuming alcohol (ethanol) may lead to an additive effect that lowers blood pressure. This may increase the likelihood of dizziness or light-headedness.

Q: Does taking Biocardis require regular doctor visits or monitoring?

Official documents describe the need for regular doctor visits and monitoring of renal function and serum potassium levels for susceptible patients. This monitoring helps ensure the medicine is working properly and checks for potential unwanted effects.

Q: Is the dose of Biocardis adjusted based on body weight?

Regulatory documents state that the antihypertensive effect of Biocardis is not influenced by body weight or body mass index. Dosing is typically determined by the indication and individual medical condition.

How should Biocardis be stored and disposed of?

Biocardis (Telmisartan) must be stored strictly according to regulatory specifications to protect the tablets from degradation, primarily due to their moisture sensitivity.

Requirement Category Official Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), with excursions allowed up to 30 C.
Packaging Protection Store in the original, sealed blister packaging to protect from moisture. Do not remove the tablet until shortly before administration.
Handling Restriction Keep from freezing. Store out of the reach and sight of children.
Disposal Instructions Unused or expired medicine must be disposed of in accordance with local, state, and federal regulations. Do not flush the tablets or dispose of them in household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biocardis found in:

A-Z Index: